Patent ID: 8653142

Claim:
A method for treating an ophthalmic disease or disorder resulting at least in part from lipofuscin pigment accumulation in an eye of a subject, comprising administering to the subject a pharmaceutical composition comprising a compound having a structure of Formula (E): as an isolated E or Z geometric isomer or a mixture of E and Z geometric isomers, as a tautomer or a mixture of tautomers, as a stereoisomer, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein: R 1 and R 2 are each the same or different and independently hydrogen; R 3 , R 4 , R 5 and R 6 are each the same or different and independently hydrogen, halogen, —OR 12 , alkyl or fluoroalkyl; R 7 and R 8 are each the same or different and independently hydrogen; each R 12 is independently selected from hydrogen or alkyl; R 14 and R 15 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR 12 , or —NR 18 R 19 ; or R 14 and R 15 form an oxo; R 16 and R 17 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR 12 , or —NR 18 R 19 ; or R 16 and R 17 form an oxo; each R 18 and R 19 are each the same or different and independently hydrogen or alkyl; t is 0, 1, 2, or 3; and each R 20 is the same or different and independently alkyl, —OR 12 , —SR 12 , alkenyl, alkynyl, halogen, fluoroalkyl, aryl or aralkyl, or two adjacent R 20 , together with the two carbon atoms to which they are attached, form a fused phenyl ring.